Bachelorarbeit, 2022
27 Seiten, Note: 2,0
1. Abstract
2. Introduction
3. Body
3.1 Basics of Immunology
3.1.1 Immunity and components of the immune system
3.1.2 Cells of the immune system
3.1.3 Cytokines
3.1.4 Recognition of microbes/pathogens
3.1.5 Phagocytosis, Opsonization and the complement system
3.1.6 Antigenicity and Immunogenicity
3.1.7 Cluster of differentiation
3.1.8 Major Histocompatibility Complex (MHC)
3.2 Antibodies
3.2.1 Antibody structure
3.2.2 Action of antibodies
3.2.3 Antibody classification and properties
4. Clinical implication and discussion
5. Results
6. Methodology
This thesis examines the fundamental immunological mechanisms underlying antibody function and evaluates the clinical utility, possibilities, and limitations of monoclonal antibodies in modern cancer diagnostics and therapeutics.
Clinical implication and discussion
Multiple clones of the same cells are where polyclonal antibodies are derived from. It consists of a diverse range of binding sites. The use of polyclonal antibodies in diagnosis is highly beneficial. Antigens can be found and identified, as well as purified and characterized, thanks to the specific antigen-antibody interaction. The low concentrations, potential for cross-reactions, and consequently reduced specificity and sensitivity of polyclonal antibodies are drawbacks when used in medical practice.
Clones of a single activated B cell are used to create monoclonal antibodies. They are capable of identifying a single unique epitope on an antigen. They have the same specificity and are identical antibodies. Hybridoma Technology, also known as the method for making monoclonal antibodies, was developed in 1975 by G J F Koehler and Caesar Milstein.
Monoclonal antibodies found their role in immunotherapy, especially making great efforts in providing better treatment options for patients suffering from cancer.
Abstract: Provides an overview of the role of monoclonal antibodies in cancer therapy and summarizes the research objectives and methodology.
Introduction: Explores the historical context of immunology and introduces monoclonal antibodies as a revolutionary tool in personalized medicine for cancer treatment.
Body: Details the complex components of the innate and adaptive immune system, the structure/function of antibodies, and the mechanism of monoclonal antibody production and application.
Clinical implication and discussion: Compares polyclonal and monoclonal antibodies and discusses the therapeutic subclasses and constraints of monoclonal antibody treatments.
Results: Synthesizes the core findings regarding the efficacy and mechanism of monoclonal therapeutic approaches in clinical settings.
Methodology: Describes the literature review process, including the evaluation of databases such as PubMed, Cochrane Library, and Google Scholar to assess current research standards.
Monoclonal antibodies, Cancer therapy, Immunology, Immunoglobulins, Antibody-drug conjugates, Clinical oncology, Antigenicity, Hybridoma technology, Targeted therapy, Immune system, Pathogen recognition, Personalized medicine.
The work focuses on evaluating the role of antibodies within immunology and their strategic application in the diagnosis and treatment of various types of cancer.
The core themes include fundamental immunology, antibody structure and classification, the specific production process of monoclonal antibodies, and their clinical efficacy against malignant tumors.
The goal is to determine how immunoglobulins can be utilized to redirect the body’s immune system to identify and neutralize cancer cells through specific signaling pathways.
The research is based on a systematic literature review, utilizing mesh search terms across major databases like PubMed, Cochrane Library, and ScienceDirect for the period of 2010 to 2022.
It provides a comprehensive analysis ranging from the "Basics of Immunology," such as cell types and the complement system, to the specific structural properties and actions of different antibody classes.
Key terms include monoclonal antibodies, cancer therapy, immunotherapy, and antibody-drug conjugates (ADCs).
Unlike non-specific therapies, monoclonal antibodies are designed to recognize and target specific antigens on cancer cells, effectively hijacking their own immune mechanisms to facilitate tumor cell destruction.
The efficacy is largely dependent on the availability of target molecules on the tumor; mutations that downregulate these proteins can result in treatment resistance and reduced therapeutic impact.
Der GRIN Verlag hat sich seit 1998 auf die Veröffentlichung akademischer eBooks und Bücher spezialisiert. Der GRIN Verlag steht damit als erstes Unternehmen für User Generated Quality Content. Die Verlagsseiten GRIN.com, Hausarbeiten.de und Diplomarbeiten24 bieten für Hochschullehrer, Absolventen und Studenten die ideale Plattform, wissenschaftliche Texte wie Hausarbeiten, Referate, Bachelorarbeiten, Masterarbeiten, Diplomarbeiten, Dissertationen und wissenschaftliche Aufsätze einem breiten Publikum zu präsentieren.
Kostenfreie Veröffentlichung: Hausarbeit, Bachelorarbeit, Diplomarbeit, Dissertation, Masterarbeit, Interpretation oder Referat jetzt veröffentlichen!

